Merck (MRK) Reports In-Line Q4 EPS; offers guidance
Tweet
Share
E-mail
Get Alerts MRK Hot Sheet
Price: $128.66 +2.56%
Revenue Growth %: +3.5%
Financial Fact:
Restructuring costs: 545.6M
Today's EPS Names:
CGEH, NAKA, APOG, More
Revenue Growth %: +3.5%
Financial Fact:
Restructuring costs: 545.6M
Today's EPS Names:
CGEH, NAKA, APOG, More
Join SI Premium – FREE
Merck (NYSE: MRK) reported Q4 EPS of $2.04, in-line with the analyst estimate of $2.04. Revenue for the quarter came in at $16.4 billion versus the consensus estimate of $16.18 billion.
GUIDANCE:
Merck sees FY2026 EPS of $5.00-$5.15, versus the consensus of $5.63. Merck sees FY2026 revenue of $65.5-67 billion, versus the consensus of $67.576 billion.
For earnings history and earnings-related data on Merck (MRK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gulfport Energy and Mobility Global to join S&P SmallCap 600
- Select Medical stockholders approve buyout by insider-led consortium
- Uranium Royalty Corp. sets shareholder vote on $1.14B Sweetwater deal
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
